Na+ CP type VIIα Inhibitors
Chemicals classified as Na+ CP type VIIα Inhibitors represent a diverse group that can interfere with sodium transport and signaling pathways. These compounds include inhibitors of epithelial sodium channels, voltage-gated sodium channels, and the Na+/K+ ATPase pump. The inhibition of these channels and pumps can indirectly affect the activity of Na+ CP type VIIα, especially if this protein is involved in maintaining sodium homeostasis, generating action potentials, or is part of a larger complex of sodium-regulating proteins.
The compounds selected work by altering the electrochemical gradient of sodium across cell membranes, which is a fundamental aspect of cellular physiology. Inhibition of ENaC by compounds like Amiloride, Phenamil, and Benzamil would reduce sodium reabsorption, which could affect the activity of Na+ CP type VIIα if it operates similarly to ENaC. In contrast, Tetrodotoxin and Lidocaine block voltage-gated sodium channels, preventing the initiation and propagation of action potentials. This action could modulate Na+ CP type VIIα if it is associated with excitability or coupled to these channels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride is known to inhibit epithelial sodium channels (ENaC), which may indirectly influence Na+ CP type VIIα activity if the protein functions similarly to ENaC. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine blocks voltage-gated sodium channels, and its action may inhibit proteins that are part of the sodium channel complex or associated signaling pathways. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain inhibits the Na+/K+ ATPase pump, which could indirectly reduce the activity of Na+-dependent proteins by altering Na+ gradients. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
12β-Hydroxydigitoxin also targets Na+/K+ ATPase, leading to increased intracellular Na+ levels, potentially affecting Na+ CP type VIIα if it relies on Na+ gradients. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil blocks L-type calcium channels; changes in Ca2+ homeostasis can indirectly influence Na+/Ca2+ exchangers and possibly Na+ CP type VIIα activity. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $109.00 | 3 | |
Ranolazine inhibits the late phase of the Na+ current in cardiac cells, which may alter the function of Na+ CP type VIIα if it is involved in cardiac sodium handling. | ||||||
Benzamil•HCl | 161804-20-2 | sc-201070 | 50 mg | $195.00 | 1 | |
Benzamil is another ENaC blocker that may also modulate the activity of Na+ CP type VIIα through its effect on sodium reabsorption and transport. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Isradipine is a calcium channel blocker, which by altering intracellular Ca2+ levels, may indirectly affect Na+ transporters or channels including Na+ CP type VIIα. | ||||||
5,5-Diphenyl Hydantoin | 57-41-0 | sc-210385 | 5 g | $70.00 | ||
Phenytoin stabilizes voltage-gated Na+ channels in their inactive state, potentially inhibiting Na+ CP type VIIα if it interacts with or is modulated by these channels. | ||||||